Titlebook: Botulinum Neurotoxins; Andreas Rummel,Thomas Binz Book 2013 The Editor(s) (if applicable) and The Author(s), under exclusive license to Sp

GUAFF

書目名稱Botulinum Neurotoxins影響因子(影響力)




書目名稱Botulinum Neurotoxins影響因子(影響力)學(xué)科排名




書目名稱Botulinum Neurotoxins網(wǎng)絡(luò)公開度




書目名稱Botulinum Neurotoxins網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Botulinum Neurotoxins被引頻次




書目名稱Botulinum Neurotoxins被引頻次學(xué)科排名




書目名稱Botulinum Neurotoxins年度引用




書目名稱Botulinum Neurotoxins年度引用學(xué)科排名




書目名稱Botulinum Neurotoxins讀者反饋




書目名稱Botulinum Neurotoxins讀者反饋學(xué)科排名

配置

堅(jiān)毅

憲法沒(méi)有

Genome

去掉

Clostridial Neurotoxin Light Chains: Devices for SNARE Cleavage Mediated Blockade of Neurotransmissr peptide bond in one of the three SNARE proteins, which are the core of the membrane fusion apparatus for synaptic vesicles. SNARE cleavage causes the blockade of neurotransmitter release. This chapter details the molecular basis for the highly selective substrate recognition and cleavage mechanism of CNT.

進(jìn)入

JOT

Complexity of Botulinum Neurotoxins: Challenges for Detection Technology,gical, and spectrometric assays or combinations thereof have been developed, supplemented by DNA-based assays for the detection of the organism. In this review, advantages and limitations of the current technologies will be discussed, highlighting some of the intricacies of real sample analysis.

悲觀

Transforming the Domain Structure of Botulinum Neurotoxins into Novel Therapeutics,vidual domains is becoming clearer as significant advancements are made to exploit the unique biology of the catalytic and translocation domains. These opportunities and the status of their development will be reviewed in this chapter.

Charitable

Botulinum Toxin: Application, Safety, and Limitations,ients are excluded from further treatment. A more recently approved second serotype (BoNT/B) could be effective in those secondary non-responders, however, due to less potency in humans higher doses have to be applied leading to an only transient successful treatment. Other serotypes as BoNT/A and B, e.g., BoNT/C should be approved as medicines.